DashboardPortfoliosWatchlistCommunityDiscoverScreener
Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
  • United States
  • Australia
  • United Kingdom
  • Canada
  • India
  • China
  • Argentina
  • Austria
  • Bahrain
  • Bangladesh
  • Belgium
  • Bermuda
  • Botswana
  • Brazil
  • Bulgaria
  • Chile
  • Colombia
  • Croatia
  • Cyprus
  • Czech Republic
  • Denmark
  • Egypt
  • Estonia
  • Finland
  • France
  • Germany
  • Ghana
  • Greece
  • Hong Kong
  • Hungary
  • Iceland
  • Indonesia
  • Ireland
  • Israel
  • Italy
  • Ivory Coast
  • Jamaica
  • Japan
  • Jordan
  • Kenya
  • Kuwait
  • Latvia
  • Lithuania
  • Luxembourg
  • Malawi
  • Malaysia
  • Malta
  • Mauritius
  • Mexico
  • Morocco
  • Namibia
  • Netherlands
  • New Zealand
  • Nigeria
  • Norway
  • Oman
  • Pakistan
  • Palestinian Authority
  • Peru
  • Philippines
  • Poland
  • Portugal
  • Qatar
  • Romania
  • Russia
  • Saudi Arabia
  • Serbia
  • Singapore
  • Slovakia
  • Slovenia
  • South Africa
  • South Korea
  • Spain
  • Sri Lanka
  • Sweden
  • Switzerland
  • Taiwan
  • Tanzania
  • Thailand
  • Trinidad & Tobago
  • Tunisia
  • Turkey
  • Uganda
  • Ukraine
  • United Arab Emirates
  • Venezuela
  • Vietnam
  • Zambia
  • Zimbabwe
  • All Industries
  • Energy
  • Oil and Gas
  • Oil and Gas Exploration and Production
  • Real Estate
  • Materials
  • Chemicals
  • Commodity Chemicals
  • Specialty Chemicals
  • Metals and Mining
  • Steel
  • Industrials
  • Aerospace & Defense
  • Aerospace and Defense
  • Building
  • Building Products
  • Construction
  • Construction and Engineering
  • Electrical
  • Electrical Components
  • Heavy Electrical Equipment
  • Industrials
  • Industrial Conglomerates
  • Machinery
  • Construction Machinery and Vehicles
  • Industrial Machinery
  • Trade Distributors
  • Trade Companies and Distributors
  • Commercial Services
  • Diversified Support Services
  • Environmental and Facilities Services
  • Office Services and Supplies
  • Professional Services
  • Research and Consulting Services
  • Marine and Shipping
  • Marine
  • Consumer Discretionary
  • Auto Components
  • Auto Parts and Equipment
  • Auto
  • Automobile Manufacturers
  • Consumer Durables
  • Leisure
  • Leisure Products
  • Luxury
  • Apparel, Accessories and Luxury Goods
  • Textiles
  • Hospitality
  • Hotels, Resorts and Cruise Lines
  • Leisure Facilities
  • Specialty Stores
  • Specialty Stores
  • Consumer Staples
  • Food and Staples Retail
  • Beverage
  • Food
  • Packaged Foods and Meats
  • Healthcare
  • Medical Equipment
  • Medical Equipment
  • Healthcare Services
  • Healthcare Distributors
  • Healthcare Facilities
  • Healthtech
  • Healthtech
  • Biotech
  • Biotech
  • Pharma
  • Pharma
  • Life Sciences
  • Clinical Research and Equipment
  • Financials
  • Diversified Financial
  • Specialized Finance
  • Capital Markets
  • Asset Management
  • Investment Banking and Brokerage
  • Insurance
  • General Insurance
  • Tech
  • IT
  • IT Consulting
  • Software
  • Application Software
  • Communications
  • Communications Equipment
  • Tech Hardware
  • Tech Hardware Storage and Peripherals
  • Electronic Equipment and Components
  • Electronic Equipment and Instruments
  • Semiconductors
  • Semiconductor Equipment
  • Semiconductors
  • Telecom
  • Entertainment
  • Movies and Entertainment
  • Interactive Media and Services
  • Interactive Media and Services
  • Media
  • Advertising
  • Publishing
  • Telecom Services and Carriers
  • Integrated Telecom Services
  • Utilities
  • Renewable Energy
Header cover image
  • DE Market
  • /
  • Healthcare

German (DAX) Biotech Industry Analysis

UpdatedSep 15, 2026
DataAggregated Company Financials
Companies14
  • 7D0.8%
  • 3M-11.7%
  • 1Y-2.4%
  • YTD-6.8%

Over the last 7 days, the Biotech industry has remained flat, although notably Vidac Pharma Holding gained 9.2%. In line with that, the industry has also been flat over the past 12 months. As for the next few years, earnings are expected to grow by 90% per annum.

Industry Valuation and Performance

Has the German Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Wed, 16 Sep 2026€3.2b€773.8m-€145,576,720.77154x-21.8x4.1x
Fri, 14 Aug 2026€3.5b€774.3m-€133,297,894.6272.6x-25.9x4.5x
Sun, 12 Jul 2026€3.6b€761.1m-€172,690,714.4978.1x-21x4.8x
Tue, 09 Jun 2026€3.5b€747.4m-€127,482,265.4573.1x-27.4x4.7x
Thu, 07 May 2026€3.8b€712.1m-€117,462,790.059.1x-32.7x5.4x
Sat, 04 Apr 2026€4.0b€742.4m-€199,728,579.903.7x-20.2x5.4x
Mon, 02 Mar 2026€3.5b€744.1m-€183,580,388.354.3x-19x4.7x
Wed, 28 Jan 2026€3.4b€744.1m-€183,444,628.464.4x-18.4x4.5x
Fri, 26 Dec 2025€3.3b€744.0m-€183,311,704.753.7x-18x4.4x
Sun, 23 Nov 2025€3.2b€748.0m-€195,508,921.103.4x-16.4x4.3x
Tue, 21 Oct 2025€3.3b€755.4m-€211,426,310.163.5x-15.5x4.3x
Thu, 18 Sep 2025€2.0b€121.4m-€184,073,205.283.2x-11x16.7x
Sat, 16 Aug 2025€3.4b€756.4m-€228,355,844.473.5x-14.9x4.5x
Mon, 14 Jul 2025€2.4b€772.7m-€178,999,093.003.9x-13.1x3x
Wed, 11 Jun 2025€2.3b€772.7m-€178,999,093.004.1x-13x3x
Fri, 09 May 2025€2.2b€836.4m-€143,205,717.0024x-15.6x2.7x
Sun, 06 Apr 2025€2.2b€818.3m-€158,890,276.0029.5x-13.8x2.7x
Tue, 04 Mar 2025€2.3b€791.9m€73.0m13.8x31x2.9x
Thu, 30 Jan 2025€2.7b€791.8m€74.2m15.1x36.5x3.4x
Sat, 28 Dec 2024€2.6b€791.8m€74.2m14.5x35.4x3.3x
Mon, 25 Nov 2024€2.5b€791.8m€74.2m12.9x34.3x3.2x
Wed, 23 Oct 2024€2.7b€866.1m€170.2m11.9x15.6x3.1x
Fri, 20 Sep 2024€2.6b€867.2m€174.8m12.2x14.9x3x
Sun, 18 Aug 2024€2.5b€868.4m€171.3m13.6x14.8x2.9x
Tue, 16 Jul 2024€2.7b€885.2m€215.0m12.6x12.6x3.1x
Thu, 13 Jun 2024€2.6b€884.7m€210.7m11.3x12.3x2.9x
Sat, 11 May 2024€2.6b€884.7m€210.7m10x12.1x2.9x
Mon, 08 Apr 2024€2.7b€773.3m€10.4m9.1x259x3.5x
Wed, 06 Mar 2024€2.6b€747.5m-€56,427,770.4012.3x-46.1x3.5x
Fri, 02 Feb 2024€2.7b€769.9m-€145,885,802.0012.9x-18.7x3.5x
Sun, 31 Dec 2023€2.9b€769.9m-€145,885,802.0013.5x-19.7x3.7x
Tue, 28 Nov 2023€2.9b€779.7m-€160,010,802.0013.7x-18.1x3.7x
Thu, 26 Oct 2023€3.7b€955.3m-€172,995,145.0010.7x-21.5x3.9x
Sat, 23 Sep 2023€3.9b€971.6m-€197,588,171.0011x-19.9x4x
  • Price to Earnings
  • Price to Sales
  • Median Price to Earnings
Price to Earnings Ratio

-19.9x


Sat, 23 Sep 2023
Total Market Cap: €3.9bTotal Earnings: -€197,588,171.00Total Revenue: €971.6mTotal Market Cap vs Earnings and Revenue0%0%0%
German Biotech Industry Price to Earnings3Y Average -3.4x202420252026
Current Industry PE
  • Investors are relatively neutral on the German Biotechs industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PS ratio of 4.1x.
Past Earnings Growth
  • The earnings for companies in the Biotechs industry have improved over the last three years.
  • Meanwhile revenues for these companies have declined 7.3% per year.
  • This means that less sales are being generated overall, but since the cost of doing business is lower, losses have been shrinking.

Industry Trends

Which industries have driven the changes within the German Healthcare industry?

DE Market-2.20%
Healthcare-0.14%
Biotech0.76%
Biotech0.76%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
T9G Vidac Pharma Holding€0.469.2%
+€2.0m
n/an/a
PA8K Paion€0.05214.1%
+€46.4k
470.7%n/a

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide

Latest News

LQ0
€0.79
Dextech Medical
7D
-6.8%
1Y
4.2%
HPHA
€2.51
Heidelberg Pharma
7D
-1.6%
1Y
-28.7%
7V0
€7.00
Novogenia
7D
-2.8%
1Y
13.8%
User avatar
New Narrative • Sep 06

Novogenia: A High-Risk, Asset-Backed Micro-Cap With Significant Optionality

Novogenia: A High-Risk, Asset-Backed Micro-Cap With Significant Optionality I do not normally write about micro-cap companies, and Novogenia AG is about as “micro” as they come. At a share price of €6.35 on 5 September 2026, its market capitalisation was approximately €76 million.
8V8
€0.028
Genetic Analysis
7D
-11.9%
1Y
-49.6%
20B
€0.28
Biomark Diagnostics
7D
-0.7%
1Y
40.1%
7ZT
€0.42
Hamlet BioPharma
7D
-2.3%
1Y
-13.9%
T5O0
€0.64
bioXXmed
7D
-18.1%
1Y
-82.7%
FYB
€20.40
Formycon
7D
-1.0%
1Y
-6.0%
User avatar
Narrative Update • Jun 26

FYB: Confirmed 2025 And 2026 Revenue Guidance Will Support Bullish Outlook

Analysts have trimmed their price target for Formycon slightly to about €39.67 from around €39.86. This reflects updated views on discount rates, growth assumptions and future P/E expectations.
T9G
€0.46
Vidac Pharma Holding
7D
9.2%
1Y
n/a
PA8K
€0.052
Paion
7D
14.1%
1Y
470.7%